Bessemer Group’s X4 Pharmaceuticals XFOR Stock Holding History

Bessemer Group’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-613	Closed	-$171K	–	1695
2020 Q2	$171K	Buy	+613	New	+$168K	﹤0.01%	1167

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Bessemer Group's XFOR Position: Q3 2020 in Review

Bessemer Group sold out of X4 Pharmaceuticals (XFOR) in Q3 2020, closing a stake of 613 shares — an estimated $171K sold.

Bessemer Group first reported a position in XFOR in Q2 2020 and held it in 1 quarter. The position peaked at $171K in Q2 2020. 53 funds tracked by Wall St. Rank hold XFOR as of Q3 2020.

Bessemer Group reported no remaining X4 Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bessemer Group sold 613 X4 Pharmaceuticals shares in Q3 2020, an estimated $171K.
Bessemer Group first reported a position in X4 Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Bessemer Group's X4 Pharmaceuticals position peaked at $171K in Q2 2020.
53 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.